ArticleADMET & DMPK2024
Pharmacokinetics and metabolism of ketoconazole after single ocular instillation in Sprague-Dawley rats.
Article in ADMET & DMPK, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Ketoconazole is limited to its conditioned oral use due to hepatic toxicity. Its ocular eye drop administration may be an option for mycotic keratitis treatment. Therefore, it is necessary to explore its pharmacokinetic and metabolic profile via topical ocular administration. Experimental approach: Nine rats were dosed at 300 μg/rat via topical ocular administration, and sacrificed at 5, 30, and 120 min with 3 rats/timepoint. Plasma, cornea, retina, and vitreous humour samples were collected, processed, and analysed. Key results: Ketoconazole was quantified with a mean peak plasma concentration of 445 ng/mL at 5 min post-dose. In the rat ocular tissue, the mean ketoconazole concentration at 5 min post-dose was 423 μg/g in the cornea, 4.96 μg/g in the retina, and 1.19 μg/g in the vitreous humour, respectively. The mean ketoconazole concentration in each matrix decreased from 5 to 120 min. The mean ketoconazole concentration at 120 min was 38.4 ng/mL in plasma, and 8.36, 0.0944, and 0.116 μg/g in the cornea, retina, and vitreous humour, respectively. Pooled plasma, cornea, retina, and vitreous humour homogenates were used for metabolite identification. Nine metabolites were identified in rat plasma, and O-dealkylated metabolite (M3) and dehydrogenated metabolite (M11) were the top two, accounting for 5.0 and 5.8 % of the relative mass abundance. The metabolic pathways were O-dealkylation, mono-oxygenation, and dehydrogenation. Eleven metabolites were identified in the rat cornea, and two metabolites were identified in the rat retina and vitreous humour, respectively. The O-dealkylated and hydrogenated metabolite (M2) was a dominant metabolite in the cornea, retina, and vitreous humour, while M3 and M11 were the dominant metabolites in plasma. Conclusion: Ketoconazole was a dominant component (≥ 98.5 %) in the cornea, retina, and vitreous humour, having higher concentrations in cornea than in plasma. M2 was identified as a dominant metabolite (1.1-1.2 %) in the cornea, retina, while M3 (5.0 %) and M11 (5.8 %) were identified as dominant metabolites in the plasma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.